ClinicalTrials.gg
Not yet recruitingNCT07508423M-OSPUpdated Apr 2, 2026

Association Between Primary Care Supply and Population Morbidity and Mortality in France at the Territorial Level

An observational study in Mortality and Morbidity, sponsored by MSPU de Pins-Justaret. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by MSPU de Pins-Justaret · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
7,000,000
Sex
All
01

Study summary

The M-OSP study investigates the association between the density of primary care professionals, including general practitioners (GPs), and population-level health outcomes across 2,850 life-health territories in France. Evidence from several OECD countries suggests higher GP density may reduce mortality, particularly cause-specific mortality such as cardiovascular deaths, but uncertainties remain regarding generalizability and other health outcomes.

This cross-sectional epidemiological study uses aggregated, territory-level data from 2009-2022, including: mortality rates (age- and sex-standardized), hospitalizations (MCO), emergency department visits, and the distribution of primary care professionals and facilities (GPs, nurses, physiotherapists, dentists, midwives, gynecologists, pediatricians, psychiatrists, and community pharmacies).

02

Conditions studied

  • Mortality
  • Morbidity
03

In context

Lead sponsor

MSPU de Pins-Justaret is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Population-wide study

Eligibility criteria

Inclusion Criteria:

All individuals affiliated with any French health insurance scheme and recorded in the Système National des Données de Santé (SNDS; French National Health Data System) through the Datamart de Consommation Inter-Régimes (DCIR; French national health insurance claims database) between January 1, 2009 and December 31, 2022

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
7,000,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality rate

    Yearly mortality rate, standardized by age group and sex

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Apr 2, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07508423
Lead sponsor
MSPU de Pins-Justaret
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Yohann Vergès, Dr
Contact
yohann.verges@dumg-toulouse.fr
0033676295896

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion